Harvard Bioscience, Inc.

What they do

Harvard Bioscience develops and sells technologies, products, and services for life science research, drug discovery, bioproduction, and preclinical testing. Its product portfolio includes telemetry systems (SoHo), cellular and molecular technology (CMT) products (including electroporation and AAA), and organoid/tissue recording platforms (MeshMEA and Incub8). The company operates in the U.S., Europe, and China, selling directly and through distributors to academic institutions, government labs, pharmaceutical, biotech, and CRO customers.

Revenue drivers

• Cellular and Molecular Technology (CMT) Products — Includes electroporation and AAA businesses; cited as a key driver of Q2 2026 growth, though higher volume of these lower-margin products pressured gross margin.
• Telemetry Products — Includes SoHo telemetry platform; part of the preclinical testing portfolio and identified as a contributor to commercial traction in Q2 2026.
• China and Geographic Mix — China outperformance in Q2 2026 boosted revenue but also contributed to an unfavorable geographic mix on gross margin.
• Consumables and Software — Recurring revenue from consumables and software was 55% of total revenues as of December 31, 2025; the company aims to expand this higher-margin segment.

Recent performance

For Q2 2026, revenue was $22.7 million, up 11% year-over-year from $20.5 million, with a 1% favorable FX impact. Net loss widened to $2.9 million from $2.3 million in Q2 2025. For the first half of 2026, revenue rose to $43.5 million from $42.2 million, and net loss narrowed to $6.3 million from $52.6 million, the prior-year period including a $48.0 million goodwill impairment. Adjusted EBITDA was $1.7 million in Q2 2026 vs. $1.5 million in the prior-year quarter. Operating cash flow in H1 2026 was negative $0.3 million, versus positive $5.7 million in H1 2025.

Strategy

The company is repositioning itself as a 'leading enabler of Translational Medicine' with four pillars: bridging in vivo and in vitro research, advancing its NPI pipeline (SoHo, MeshMEA, Incub8), expanding consumables/software revenue, and driving operational excellence. It plans to use its preclinical business as a cash-generative foundation to fund R&D and bolt-on acquisitions. In January 2026, it initiated Project Viking, consolidating manufacturing from Holliston, MA to Minneapolis, MN and relocating some operations to Germany, Sweden, and the UK, targeting $3 million savings in 2027 and $4 million annually starting 2028. The company also completed a debt refinancing on December 17, 2025.

Risks

• Highly Competitive Industry — Competitors with greater financial, technical, and marketing resources may undercut pricing or introduce superior products, eroding market share.
• Rapid Technological Change — New or improved products from competitors could render Harvard Bioscience's products obsolete or less competitive.
• Customer Demand Shifts — Changing customer preferences, including demand for environmentally friendly products, could reduce demand for current offerings.
• Execution of Restructuring — The Project Viking manufacturing consolidation may fail to deliver expected cost savings or disrupt production and customer relationships.

Outlook

Management raised full-year 2026 revenue guidance to 3%-5% year-over-year growth, while maintaining its adjusted EBITDA growth target of 6%-10%. Full-year adjusted gross margin guidance is now 57%-59%, reflecting higher-volume lower-margin CMT and geographic mix. For Q3 2026, the company expects revenue of $21.0-$22.6 million, adjusted gross margin of 56%-58%, and adjusted EBITDA of $1.5-$2.5 million.